The effect of enoxaparin sodium (Clexane) on the incidence of deep vein thrombosis following electrophysiology studies and radiofrequency ablation

Trial Profile

The effect of enoxaparin sodium (Clexane) on the incidence of deep vein thrombosis following electrophysiology studies and radiofrequency ablation

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 May 2013

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Deep vein thrombosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top